MEDXFMedexus Pharmaceuticals Inc

About Medexus Pharmaceuticals Inc (MEDXF)

Medexus Pharmaceuticals Inc (MEDXF) is a Drug Manufacturers - Specialty & Generic company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the OTCQX tier.

Medexus Pharmaceuticals, Inc. is a rapidly growing, commercial-stage specialty pharmaceutical company with an established presence across North America that is focused on therapeutic areas rheumatology, auto-immune disease, specialty oncology, allergy, and pediatric diseases.

Products and services

IXINITY® is a third-generation recombinant human coagulation factor IX approved by the FDA in April 2015 in the United States for the control and prevention of bleeding episodes and for perioperative management in adults and children 12 years of age or older with Hemophilia B. Gleolan™ is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III and IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. Rasuvo® is a weekly, subcutaneous, single-dose injector of methotrexate that is approved in the United States for the treatment of rheumatoid arthritis, psoriasis and JIA. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached subcutaneous needle that is approved in Canada for the treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis. RupallTM On January 25, 2017, RupallTM (rupatadine) was commercially launched in Canada. RupallTM comes in two dosage forms; the tablet 10mg and oral solution 1mg/mL and is indicated for the relief of the symptoms associated with Seasonal Allergic Rhinitis (“SAR”), Perennial Allergic Rhinitis (“PAR”) and Chronic Spontaneous Urticaria (“CSU”) in patients 2 years of age and older. Treosulfan is an innovative, orphan-designated, bifunctional alkylating agent developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation.

MEDXF key facts

Ticker symbol

MEDXF

Market tier

OTCQX

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2013

Employees

82

Estimated market cap

$49.36M (as of Apr 10, 2025)

Shares outstanding

32,258,353

Reporting standard

International Reporting: Toronto Stock Exchange

Audit status

Audited

Fiscal year end

3/31

Latest filing

Quarterly Report (Dec 31, 2024)

Medexus Pharmaceuticals Inc leadership

• Ken d'Entremont — CEO
• Richard Labelle — COO
• Brendon Jeffrey Buschman — CFO
• Ian Wildgoose Brown — General Counsel
• Accounts Payable — Other

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with M